

Diagnosis and Treatment of Juvenile Idiopathic Arthritis: **2008**

Compiled by Kristin Hayward, MD and Carol Wallace, MD

CLASSIFICATION/OUTCOMES:

1. [Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al.](#) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. *Arthritis Rheum.* 2008; 58:15-25.
2. [Petty RE, Southwood TR, Manners P, et al.](#) International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. *J Rheumatol.* 2004;31:390-392.
3. [Minden K, Kiessling U, Listing J, Baum J, Glass DN, Goldenberg J, et al.](#) Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthritis. *J Rheumatol.* 2000;27:2256-2263.
4. [Packham JC, Hall MA.](#) Long-term follow-up of 246 adults with juvenile idiopathic arthritis: Functional outcome. *Rheumatology (Oxford).* 2002;41:1428-1435.
5. [Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH.](#) Patterns of clinical remission in select categories of juvenile idiopathic arthritis. *Arthritis Rheum.* 2005;52:3554-3562.
6. [van Rossum MA, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJ, Franssen MJ, et al.](#) Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: Sustained benefits of early sulfasalazine treatment. *Ann Rheum Dis.* 2007;66:1518-1524.

STANDARD MEDICAL TREATMENT REVIEWS:

7. [Haines KA.](#) Juvenile idiopathic arthritis: Therapies in the 21st century. *Bull NYU Hosp Jt Dis.* 2007;65:205-211.
8. [Hashkes PJ, Laxer RM.](#) Medical treatment of juvenile idiopathic arthritis. *JAMA.* 2005;294:1671-1684.
9. [Wallace CA.](#) Current management of juvenile idiopathic arthritis. *Best Pract Res Clin Rheumatol.* 2006;20:279-300.

DEFINING RESPONSE AND REMISSION:

10. [Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A.](#) Preliminary definition of improvement in juvenile arthritis. *Arthritis Rheum.* 1997;40:1202-1209.
11. [Brunner HI, Lovell DJ, Finck BK, Giannini EH.](#) Preliminary definition of disease flare in juvenile rheumatoid arthritis. *J Rheumatol.* 2002;29:1058-1064.

12. [Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group.](#) Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. *J Rheumatol.* 2004;31:2290-2294.

13. [Ringold S, Wallace CA.](#) Measuring clinical response and remission in juvenile idiopathic arthritis. *Curr Opin Rheumatol.* 2007;19:471-476.

TNF-ALPHA ANTAGONISTS:

14. [Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al.](#) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. *Ann Rheum Dis.* 2008.

15. [Prince FH, Twilt M, Ten Cate R, Van Rossum MA, Armbrust W, Hoppenreijns EP, et al.](#) Long-term follow-up on effectiveness and safety of etanercept in JIA: The Dutch national register. *Ann Rheum Dis.* 2008.

16. [Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al.](#) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. *N Engl J Med.* 2000;342:763-769.

17. [Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al.](#) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. *Arthritis Rheum.* 2008;58:1496-1504.

18. [Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al.](#) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. *Arthritis Rheum.* 2007;56:3096-3106.

19. [van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G, et al.](#) Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. *Ann Rheum Dis.* 2007;66:253-256.

20. [Gerloni V, Pontikaki I, Gattinara M, Fantini F.](#) Focus on adverse events of TNF{alpha} blockade in JIA in an open monocentric long-term prospective study of 163 patients. *Ann Rheum Dis.* 2008;67:1145-52.

21. [Lovell DJ, Ruperto N, Goodman S, et al.](#) Adalimumab is Safe and Effective During Long-term Treatment of Patients with Juvenile Rheumatoid Arthritis: Results from a 2-year Study. *Arthritis Rheum.* 2007;56:S292.

22. [Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al.](#) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. *N Engl J Med.* 2008;359:810-20.

23. [Kanakoudi-Tsakalidou F, Tzimouli V, Pratsidou-Gertsis P, Chronopoulou E, Trachana M.](#) The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment. *Cytokine* 2008;42:293-297.

24. Giannini E, Ilowite N, Lovell D, Wallace C, Rabinovich C, Reiff A, et al. The Long-term Safety of Etanercept in Children with Polyarticular or Systemic Juvenile Rheumatoid Arthritis. Interim results of a 3-year, open-label registry. Oral Presentation, ACR Keystone Pediatric Rheumatology Symposium, Keystone, CO, 2008.

ANTI-IL-1 AGENTS:

25. [Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J.](#) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. *J Exp Med.* 2005;201:1479-1486.

26. [Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al.](#) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: Preliminary experience in France. *Ann Rheum Dis.* 2008;67:302-308.

27. [Gattorno M, Piccini A, Lasigliè D, Tassi S, Brisca G, Carta S, et al.](#) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. *Arthritis Rheum.* 2008;58:1505-1515.

28. Lovell DJ, Giannini EH, Kimura Y, et al. Preliminary Evidence for Sustained Bioactivity of IL-1 Trap (Riloncept), A Long Acting IL-1 Inhibitor, In Systemic Onset Juvenile Idiopathic Arthritis (SJIA). *Arthritis Rheum.* 2007;56:S514

ABATACEPT:

29. Giannini EH, Ruperto N, Prieur AM, et al. Efficacy of Abatacept in Different Sub-Populations of Juvenile Idiopathic Arthritis (JIA): Results of a Randomized Withdrawal Study. *Arthritis Rheum.* 2007;56:S291.

30. Lovell DJ. Treatment of Recalcitrant JIA. Oral Presentation, ACR Keystone Pediatric Rheumatology Symposium, 2008.

31. Lovell DJ, Ruperto N, Prieur AM, et al. Abatacept Treatment of Juvenile Idiopathic Arthritis (JIA): Safety Report. *Arthritis Rheum.* 2007;56:S292.

32. [Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, et al.](#) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. *Lancet* 2008;372:383-91.

RITUXIMAB:

33. [Kuek A, Hazleman BL, Gaston JH, Ostör AJ.](#) Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. *Rheumatology (Oxford)* 2006;45:1448-1449.
34. [El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, et al.](#) Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. *J Pediatr.* 2007;150:376-382.
35. [Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, et al.](#) Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. *Blood.* 2006;107:2639-2642.
36. [Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, et al.](#) Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. *Pediatr Blood Cancer.* 2008;50:822-825.

ANTI-IL-6 AGENTS:

37. [Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al.](#) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled, withdrawal phase III trial. *Lancet* 2008;371:998-1006.

LEFLUNOMIDE:

38. [Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, et al.](#) Leflunomide or methotrexate for juvenile rheumatoid arthritis. *N Engl J Med.* 2005;352:1655-1666.

THALIDOMIDE/LENALIDOMIDE:

39. [Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC.](#) Thalidomide and lenalidomide: Mechanism-based potential drug combinations. *Leuk Lymphoma.* 2008:1-8.
40. [García-Carrasco M, Fuentes-Alexandro S, Escárcega RO, Rojas-Rodríguez J, Escobar LE.](#) Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis. *Joint Bone Spine.* 2007;74:500-503.
41. [Lehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttenlocher A, Onel KB.](#) Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. *J Pediatr.* 2004;145:856-857.

ASCT:

42. [De Kleer IM, Brinkman DM, Ferster A, Abinun M, Quartier P, Van Der Net J, et al.](#)
Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: Analysis of clinical effects, mortality, and transplant related morbidity. *Ann Rheum Dis.* 2004;63:1318-1326.

43. [Brinkman DM, de Kleer IM, ten Cate R, van Rossum MA, Bekkering WP, Fasth A, et al.](#)
Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: Long-term follow-up of a prospective clinical trial. *Arthritis Rheum.* 2007;56:2410-2421.